Announcements
On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 13 Article 7
Back to Table of Contents
Previous

Eurosurveillance, Volume 22, Issue 13, 30 March 2017
Miscellaneous
Eurosurveillance editorial team: Call for papers for a special issue on screening and prevention of communicable diseases in newly arrived migrants in Europe

+ Author affiliations


Citation style for this article: Eurosurveillance editorial team. Call for papers for a special issue on screening and prevention of communicable diseases in newly arrived migrants in Europe. Euro Surveill. 2017;22(13):pii=30500. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.13.30500


Eurosurveillance invites authors to submit papers for a special issue on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe.

According to the office of the United Nations High Commissioner for Refugees, the levels of displaced people are currently the highest ever recorded worldwide (http://www.unhcr.org/afr/figures-at-a-glance.html).

Since 2015, Europe has experienced an unprecedented increase in the numbers of newly arrived migrants. For example between 2015 and early 2016, over 1.2 million people arrived in Europe. In 2016 alone a total of 355,361 people arrived by sea in countries belonging to the European Union (EU), landing on the coasts of the Mediterranean sea. Over 900 were officially reported to have died or gone missing during their journey (http://data2.unhcr.org/en/situations/mediterranean#_ga=1.123760719.43188132.1490861483).

Reasons for migration are diverse and include seeking refuge and/or asylum from conflict, violence and persecution.

While most migrants are healthy, some sub-groups of migrants are disproportionally affected by certain diseases. The overwhelming share of health problems for newly arrived migrants in Europe are non-communicable diseases and chronic conditions along with mental disorders, and malnutrition. There is a debate among public health experts as to what screening and prevention measures should be offered to migrants to maintain a high level of public health in general and to improve the health of the newly arrived migrants to the EU/ European Economic Area in particular.

In order to contribute to the current body of evidence, the special issue on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe, Eurosurveillance aims to provide new insights and aspects that could spark scientific debate and support decision making.

Topics of interest may include, but are not limited to, the following diseases/conditions/subjects:

  • Active and latent tuberculosis

  • HIV/AIDS

  • Hepatitis B

  • Hepatitis C

  • Vaccine-preventable diseases

  • Intestinal parasites

  • Feasibility, acceptability and cost effectiveness

The submission deadline is 1 July 2017. If you would like to submit a paper or ask for more information, please see our instructions for authors regarding article formats and contact the editorial team at .




Back to Table of Contents
Previous

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.